Product
LM-108
4 clinical trials
2 indications
Indication
Advanced Solid TumorIndication
Triple-Negative Breast CancerClinical trial
A Phase I/II, Open-Label, Dose Escalation and Expansion Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-10-06
Clinical trial
A Phase I/II, Open-Label, Dose-Escalation and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Toripalimab in Advanced Solid TumoursStatus: Recruiting, Estimated PCD: 2025-07-24
Clinical trial
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid TumoursStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Phase II Single Center Two Cohorts Trial of LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast CancerStatus: Recruiting, Estimated PCD: 2026-04-01